Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 12/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112937 | 1.00 | KCNQ2 (0.39) | KCNQ2LMNAGAAALOX5EPHX2 | |
| SCHEMBL3101696 | 0.89 | KCNQ2 (0.40) | KCNQ2LMNAGAAALOX5EPHX2 | |
| SCHEMBL30794764 | 0.89 | KCNQ2 (0.40) | KCNQ2LMNAGAAALOX5EPHX2 | |
| SCHEMBL3109667 | 0.86 | MAPK1 (0.38) | KCNQ2LMNAGAAALDH1A1MAPT | |
| SCHEMBL30814210 | 0.86 | MAPK1 (0.38) | KCNQ2LMNAGAAALDH1A1MAPT | |
| SCHEMBL30814227 | 0.83 | ALOX5 (0.50) | KCNQ2ALOX5EPHX2KCNT1ALDH1A1 | |
| SCHEMBL3094685 | 0.83 | ALOX5 (0.50) | KCNQ2ALOX5EPHX2KCNT1ALDH1A1 | |
| SCHEMBL30794362 | 0.80 | KCNQ2 (0.46) | KCNQ2ALOX5EPHX2KCNT1KCNQ3 | |
| SCHEMBL3099402 | 0.80 | KCNQ2 (0.46) | KCNQ2ALOX5EPHX2KCNT1KCNQ3 | |
| SCHEMBL30794875 | 0.80 | KCNQ2 (0.38) | KCNQ2LMNAGAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |